Wockhardt is a leading, research-based, global enterprise with relevance in the fields of pharmaceuticals, biotechnology, and healthcare services. Our multinational R&D and manufacturing facilities are spread across India, USA, UK and UAE, and our worldwide marketing presence includes over 30 countries across 6 continents.

D-4 MIDC, Chikalthana Chhatrapati Sambhajinagar, 431006, India 91-22-2653 4444 [email protected] Corporate Identity Number: L24230MH1999PLC120720

Wockhardt is a fully integrated, innovation-led company committed to provide high quality biological products at an affordable price for needy patients and healthcare systems across the globe. Wockhardt holds 45 patents in biosimilar and biobetter development phase.

Dr. Habil Khorakiwala founded Wockhardt in 1967. Today, the Wockhardt Group is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology, Active Pharmaceutical Ingredients (APIs), and Super Speciality Hospitals.

The team has proven expertise in developing products using yeast, E. coli and mammalian cell culture expression platforms. The efforts of Wockhardt in Biotechnology space have been well recognized. We also have a robust pipeline of recombinant therapeutic proteins for major healthcare needs.

He founded Wockhardt in 1967. Today, the Wockhardt Group is India’s leading research-based, global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology, Active Pharmaceutical Ingredients (APIs), and Super Speciality Hospitals.

Wockhardt is a fully integrated, innovation-led company committed to provide high quality biological products at an affordable price for needy patients and healthcare systems across the globe. Wockhardt holds 45 patents in biosimilar and biobetter development phase.

[email protected] Corporate Identity Number: L24230MH1999PLC120720. Wock Stock. send ...

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt’s New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status

Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales Author – Shazad Mushtaq, Paolo Garello, Anna Vickers, Neil Woodford, David M Livermore Journal Name – Journal of Antimicrobial Chemotherapy Citation – 2022, 77(10), 2772–2778 Read More Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β ...